Mazdutide, the 'miracle' injection to lose up to 15% of weight created by China
A new obesity medication, Mazdutide, developed by China’s Innovent Biologics and Eli Lilly, has shown significant weight loss results and is on track for approval in China.
Losing too much weight with weight-loss pens worries doctors
Recent findings raise concerns among doctors regarding weight-loss medications that may cause excessive weight loss.
Novo Nordisk's shares plummet more than 16% after results of new drug
Novo Nordisk's shares sharply declined following disappointing clinical trial results of its new weight-loss drug, CagriSema, which underperformed compared to a competitor's product.
Novo Nordisk: 15% Drop in Stock - Why the Clinical Trial of CagriSema Was Disappointing
Novo Nordisk's stock plummeted 15% after its new drug CagriSema failed to meet key weight-loss targets in a clinical trial compared to Eli Lilly's tirzepatide.
Novo Nordisk sinks again on the stock market after failing trials for its new obesity drug
Novo Nordisk's shares dropped significantly after the company reported failures in trials for its experimental obesity drug, CagriSema.
What if weight loss medications work too well?
There are emerging concerns regarding weight loss medications, which, while effective, may lead to unhealthy weight loss and eating disorders.
Problem with obesity drugs: patients lose too much weight, get scared, and stop taking them
A new obesity drug trial reveals significant weight loss but raises concerns as patients abandon the study due to fears of losing too much weight.
New concerns about weight loss drugs: What happens if they work... too well?
Recent trials involving the weight loss drug retatrutide have raised concerns after participants reported significant weight loss, but also higher than normal dropout rates due to side effects.
New concerns about weight loss medications: What happens if they work too well?
Recent trials of a weight loss drug called retatrutide show significant weight loss, raising concerns among researchers about the potential for excessive weight loss and related side effects.
Eli Lilly or Novo Nordisk? The stock market has mercilessly decided
The market for weight-loss injections is expanding, but investors have decisively favored one pharmaceutical giant over the other.
How the drugs that will revolutionize obesity treatment work
Semaglutide by Novo Nordisk is the first drug approved for obesity treatment that achieves weight loss comparable to bariatric surgery, while Eli Lilly's tirzepatide is expected to gain approval soon after showing efficacy and safety in clinical trials.
The US FDA requests the removal of the 'suicidal thoughts' warning from weight loss drugs
The FDA has requested pharmaceutical companies to remove warnings about potential suicidal thoughts from labels of common weight-loss medications, including Novo Nordisk's 'Wegovy' and Eli Lilly's 'Zyban', following a comprehensive review that found no link to such thoughts.
Novo Nordisk achieves a pyrrhic victory with Wegovy pills
Novo Nordisk's new oral obesity drug Wegovy offers only a minor advantage over Eli Lilly in the ongoing pharmaceutical battle for obesity treatments.